Maravai LifeSciences (MRVI) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRVI shares.
View MRVI analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12 month target prices for Maravai LifeSciences' shares. Their MRVI share price forecasts range from $14.00 to $29.00. On average, they predict the company's share price to reach $19.80 in the next year. This suggests a possible upside of 48.5% from the stock's current price.
View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts.

Maravai LifeSciences' stock was trading at $14.31 on January 1st, 2023. Since then, MRVI shares have decreased by 6.8% and is now trading at $13.33.
View the best growth stocks for 2023 here.

Maravai LifeSciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 7,270,000 shares, an increase of 21.2% from the April 30th total of 6,000,000 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 6.7% of the company's stock are short sold.
View Maravai LifeSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MRVI earnings forecast.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its quarterly earnings results on Monday, May, 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.01. The business had revenue of $79.03 million for the quarter, compared to analyst estimates of $79.72 million. Maravai LifeSciences had a net margin of 21.36% and a trailing twelve-month return on equity of 38.41%. The business's quarterly revenue was down 67.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.54 earnings per share.

ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Direxion mRNA ETF (MSGR), Janus Henderson Small Cap Growth Alpha ETF (JSML), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Putnam BioRevolution ETF (SYNB), Distillate Small/Mid Cash Flow ETF (DSMC), Renaissance IPO ETF (IPO), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) and Vanguard U.S. Quality Factor ETF (VFQY).

Maravai LifeSciences updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of $0.27-$0.33 for the period, compared to the consensus EPS estimate of $0.35. The company issued revenue guidance of $400.00 million-$440.00 million, compared to the consensus revenue estimate of $430.17 million.

(MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI."

Maravai LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Thrivent Financial for Lutherans (3.21%), BlackRock Inc. (2.31%), JPMorgan Chase & Co. (1.52%), Clearbridge Investments LLC (1.27%), Renaissance Technologies LLC (1.25%) and Mackenzie Financial Corp (0.99%).

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRVI stock can currently be purchased for approximately $13.33.

Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $3.35 billion and generates $883 million in revenue each year. The company earns $220.21 million in net income (profit) each year or $1.15 on an earnings per share basis.

The company employs 470 workers across the globe.

Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com.